Etranacogene dezaparvovec (Hemgenix)
Jump to navigation
Jump to search
History of changes in EMA indication
- 2/20/2023: Granted conditional authorisation for the treatment of severe and moderately severe Haemophilia B (congenital Factor IX deficiency) in adult patients without a history of Factor IX inhibitors.